plete response that lasted 6 years.' However, some patients relapsed with Id-negative disease. In these cases, the malignant clone no longer expressed the idiotypic determinant to which the MoAb had been generated, despite the expression of SIg.' Additional analysis revealed that ongoing somatic mutations in the variable-region genes contributed to the loss of Id expression." Subsequent investigations of antiId therapy combined with interferon alfa or chlorambucil resulted in response rates (complete plus partial) of 69%; however, Id-negative relapse was not prevented.' 'J' Based on the known sensitivity of lymphoma to radiation and the capability of labeling MoAbs with a variety of radioisotopes,13 several clinical trials using radiolabeled anti-B- anti-Id MoAbs demonstrated excellent in vivo stabilii, produced significantly tumor regression in three of nine patients, exhibited acceptable toxicities, and elicited no HAMA formation. Further investigation of repetitive, low-dose anti-Id and MoAb therapy is warranted; however, the advantages of a pan B MoAb may prove the latter to be the agent of choice for the radioimmunotherapy of B-cell lymphoma.
A clonal antibodies (MoAbs) began over a decade ago with a MoAb reactive with a B-cell antigen.' Additional studies of unconjugated antibodies directed at B-cell surface molecules have shown antitumor a~tivity.'.~ Tumor-specific anti-idiotype (anti-Id) MoAbs have been developed that are directed against the variable-region antigenic determinants of the clonal surface Ig (SIg) of malignant B cells.',' In clinical trials, these MoAbs resulted in significant responses in a majority of patients, with one patient undergoing a complete response that lasted 6 years.' However, some patients relapsed with Id-negative disease. In these cases, the malignant clone no longer expressed the idiotypic determinant to which the MoAb had been generated, despite the expression of SIg.' Additional analysis revealed that ongoing somatic mutations in the variable-region genes contributed to the loss of Id expression." Subsequent investigations of antiId therapy combined with interferon alfa or chlorambucil resulted in response rates (complete plus partial) of 69%; however, Id-negative relapse was not prevented.' 'J' Based on the known sensitivity of lymphoma to radiation and the capability of labeling MoAbs with a variety of radioisotopes,13 several clinical trials using radiolabeled anti-Bcell MoAbs have been initiated with promising result^.^^-'^ To date, most trials with radiolabeled MoAbs in B-cell lymphoma have used the radioisotope I3'I. Antibodies labeled with 13'1 are not ideal candidates for radioimmunotherapy, because of in vivo dehal~genation.'~.'~ Furthermore, yirradiation results in total-body irradiation to the patient and radiation exposure to the surrounding personnel, and requires hospitalization for doses greater than 30 mCi.
In the pilot trial of '"Y-labeled anti-Id MoAb therapy in relapsed B-cell lymphoma, our group chose '"Y, a pure pemitter, because of its favorable chelation characteristics, @-hour half-life (and therefore relatively rapid rad dose delivery rate), lack of y-irradiation (except for Bremsstrahlung), obviating the need for extensive shielding or hospitalization, and E,,, of 2.3 MeV and E,,, of 934 keV, sufficient to deliver a radiation effect over a distance of 100 to 1,000 cell diameters. Because of the field effect of radiation, radiolabeled anti-Id therapy was thought to have a potential advantage over the naked MoAb by destroying not only Idpositive target cells but also any bystander Id-negative tumor cells, theoretically overcoming the limitation of idiotypenegative relapse. For tumor targeting, "'In, a y-emitting isotope shown by multiple animal studies'' to have a biodistribution nearly identical to that of '"Y-MoAb, was bifunctionally attached to the MoAb for radioimmunoscintigraphy (RIS). Idiotypic determinants have been identified that are shared by more than one lymphoma and are found in low concentrations in normal circulating Ig." MoAbs to these shared Ids (sIds) have been termed anti-sIds. In contrast, MoAbs reactive with an idiotype from an individual patient's lymphoma and not reactive with lymphomas from other patients are called anti-private Id (anti-pId) MoAbs. Anti-sIds expand the candidate patient population for therapy by obviating the requisite lengthy waiting period for a customized anti-pId and by providing the capacity for off-the-shelf therapy for one in three patients. The anti-sIds used in this study were chosen from a panel of sIds developed for this investigation.
In this report, toxicity, tumor targeting, dosimetry, and tumor response data in nine patients imaged with "'In antiId and treated with MoAbs are reported. MoAbs to both pIds and sIds were used for imaging and therapy.
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MATERIALS AND METHODS
Patient eligibility.
Patients were required to have histologically confirmed B-cell non-Hodgkin's lymphoma and to have failed to respond to at least one standard chemotherapy. Prior radiation therapy was allowed. Each lymphoma was reactive with an available anti-sId or a customized anti-p1d.I' Each patient had measurable disease, an Eastern Cooperative Oncology Group performance status of 0 to 2, and an age more than 18. If a pId was used, a serum pId level of less than 50 pglmL at the time of MoAb treatment was required. This requirement was eliminated for patients treated with sIds, since assays for circulating sIds yielded conflicting results depending on methodology. All patients had granulocyte counts of at least 1,500/pL, platelet at least 100,OOO/pL, serum creatinine not greater than 2.0 mg/dL and serum bilirubin not greater than 1.5 mg/ dL. Malignant cells in the bone marrow were allowed. All patients provided informed consent, and this protocol was approved by the University of California, San Diego, and San Diego Regional Cancer Center Committees on Investigations Involving Human Subjects and the Radiation Safety Committees of the University of California, San Diego, Medical Center and the San Diego Veterans Administration Medical Center. A US Food and Drug Administration Investigational New Drug Application, held by IDEC Pharmaceuticals Corp (Mountain View, CA), was obtained for this study.
Anti-Id MoAbs were prepared in collaboration with IDEC Pharmaceuticals Corp, as described prev i o~s l y .~~~' Anti-pIds were generated specifically for the individual patient, and anti-sIds were generated for another patient's lymphoma but were found to be cross-reactive with the patient's lymphoma in this trial.lX Mouse hybridoma clones were screened by enzymelinked immunosorbent assay (ELISA) for anti-Id specificity. AntisId MoAbs were selected by a two-stage screening procedure." MoAbs were grown in vitro using hollow-fiber bioreactors." Crude MoAb-containing supematant was purified using NH4S04 precipitation or a protein A affinity chromatography step followed by ion exchange. The MoAb was more than 90% pure Ig as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and passed general safety, sterility, and endotoxin testing. The preparation was found to be free of adventitious viruses. Chelation and conjugation of the anti-Id MoAbs to "'In and to was performed in collaboration with Hybritech Inc (San Diego, CA) as described Isothiocyanatobenzyl DTPA was used as the chelating agent. Each MoAb was successfully coupled with "'In and 'q, and the immunoreactivity of chelated MoAbs was in excess of 65% based on the fraction of radiolabeled MoAb capable of binding to Id protein immobilized on a solid-phase matrix. Biodistribution studies in normal CD-I mice confirmed the stability and similarity of the behavior of "'In and conjugates in vivo. Specific activity of the conjugates was 1.25 mCi/mg for "'In anti-Id MoAb and 30 mCi/mg for anti-Id MoAb on the day of calibration. Treatment plan. Patients with detectable levels of circulating Id were treated with unlabeled MoAb in amounts sufficient to result in clearing of the pId or to result in the presence of free circulating MoAb. To identify optimal conditions for targeting, some patients received two imaging doses of "'In MoAb and total-body scans were performed. When two doses were used, an initial clearing dose of 50 mg unlabeled, MoAb was administered followed by 0.5 mCi "'In-labeled MoAb, and total-body imaging was repeated. A second dose of at least 500 mg clearing MoAb was then administered, followed by approximately 5 mCi '"In-labeled MoAb and totalbody imaging. The imaging protocol is described later. All patients were premedicated with acetaminophen and diphenhydramine.
Unlabeled anti-Id MoAb was diluted in 500 mL normal saline and infused at a maximum rate of 150 mg/h. "'In anti-Id MoAb Anti-Id MoAb preparation.
Preparation of goY-and "'In-labeled anti-Id MoAb.
was diluted in 6.5 mL aqueous buffer solution containing human serum albumin and administered intravenously (IV) as a bolus over 5 minutes at the end of infusion.
MoAb was diluted in a 2.5-mL aqueous solution containing human serum albumin and administered as an IV bolus over 5 minutes at the end of infusion. The same quantity of unlabeled anti-Id or anti-sId MoAb used preimaging was used for "Y MoAb infusion.
Each patient underwent serial y-camera RIS (Elscint [Haifa, Israel] or General Electric [Milwaukee, WI] large-field-of-view camera) at 2 hours, 24 hours, and additional time points, often through 144 hours post infusion, to evaluate changes in tracer distribution in the various organs and to determine optimal imaging time for tumor targeting. Five of nine patients underwent dosimetric estimates of radiation-absorbed doses to normal organs and to tumor sites (see below). Imaging scans were all interpreted by the same nuclear medicine physician (S.E.H.), who was aware of the patient's sites of disease, by conventional radiographic imaging. Only patients judged to have targeting of a majority of tumor sites were allowed to proceed to the therapy phase of the study.
Standard bone marrow harvesting techniques were used. The initial seven patients, after imaging of radiolabeled MoAb in tumor sites, proceeded to bone marrow harvesting (if not previously performed) as a precaution for possible severe myelosuppression.z122 Following harvesting, patients underwent initial WY-labeled anti-Id MoAb therapy beginning with a 10 to 15-mCi dose. Each patient was monitored weekly for toxicity with complete blood counts, chemistry panel, and urinalysis. Cycles of imaging with "'In MoAb and treatment with
MoAb were repeated every 6 to 8 weeks. Doses of MoAb were escalated by 5 mCi in patients if continued targeting could be demonstrated and if toxicities were reversible and acceptable (maximum grade 3 nonhematologic toxicity and maximum grade 4 hematologic toxicity lasting < 14 days). Cycles of imaging and therapy were administered in the outpatient setting for eight of nine patients. Serum Id levels were determined by ELISA as previously de~cribed.'~ The capture protein was immobilized on a 96-well plate (Dynatech Laboratories, Chantilly, VA) by incubating 100 &well in 0.05 molL carbonate buffer, pH 9.6, overnight at 4°C. Serum samples were diluted in sample buffer consisting of phosphate-buffered saline (PBS) supplemented with 1% bovine serum albumin (Sigma Chemical Co, St Louis, MO), and 5O/pL/well was added to the plate for 30 minutes at 37°C. The plates were washed with buffer composed of PBS supplemented with 1% Tween 20 (Sigma Chemical Co). A 1 :5,000 dilution of horseradish peroxidase (HRP)-conjugated goat antihuman IgM or IgG (Sigma Chemical Co) was added to the plate at 50 pL/well for 30 minutes at 37°C. The plates were again washed with wash buffer and 150 pL 3.7-mmoK o-phenylenediamine in 0.1 moVL citrate buffer, pH 5.0. HZOZ (0.012%) was added to each well and incubated in the dark at room temperature for 15 minutes. The reaction was stopped by addition of 2.5N H2S04, and absorbance at 490 nm was determined on an automatic ELISA reader (Molecular Devices, Menlo Park, CA).
Murine Ig levels were determined as described earlier, using 100 nglwell goat antimouse IgG ( T A W Inc, Burlingame, CA) as the capture antibody and a 1:5,000 dilution of HRP-conjugated goat antimouse IgG (Sigma Chemical Co) as the secondary antisera. Human antimouse antibodies (HAMA) were determined as described earlier, using 100 nglwell anti-Id as the capture antigen and a 1:5,000 dilution of HRP-conjugated goat antihuman K or A light chain (Sigma Chemical Co) as the secondary antisera. Antisera against the nonId light chain was used in the HAMA ELISA.
Indirect immunofluorescence staining was performed as previously de~cribed.'~ MoAbs to CP3, CD4, CD5, CD19, and CD20 (Coulter Immunologics, Hialeah, FL) and human IgM, IgG, IgD, K,
Immunological monitoring and pharmacokinetic studies.
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From 3642 WHITE ET AL and X (AMAC Inc, Larabee, Westbrooke, ME) were used in the procedures. Cells (lo6 in 25 pL) were incubated with 50 pL containing 500 ng MoAb for 30 minutes at 4°C. The cells were washed twice in 1 mL PBS supplemented with 10% calf serum (Gemini Bioprcducts, Calabasas, CA) and 0.1% sodium azide, and were resuspended in 75 pL 2O-pghL phycoerythrin-conjugated goat (Fab'h antimouse IgG (TAG0 Inc.) for 30 minutes at 4°C. The cells were again washed twice and were fixed by resuspending in 1 mL 1 % formaldehyde. The cells were then analyzed by flow cytometry on an EPICS Profile (Coulter Immunologics).
A biopsy of a lymphoma site was obtained from one patient (no. 5 ) 48 hours after infusion of 500 mg anti-pld MoAb and 4.7 mCi "In anti-pld MoAb, and was compared with lymphoma cells obtained before therapy. The remainder of the biopsy was then cryopreserved in dimethylsulfoxide. Indirect immunofluorescence staining of preinfusion and postinfusion lymphoma specimens was performed as described earlier.
A portion of the postinfusion lymphoma specimen was weighed and then counted in a gamma counter to determine the amount of isotope present in the tissue as a percentage of injected dose per gram of tissue.
Pharmacokinetics of radiolabeled MoAbs were determined by obtaining blood at specified times (maximum, five time points) following injection. Radioactivity in I mL serum was assayed at each time point by counting the aliquot against a standard made from injected material. The patient's blood volume was estimated from lean body mass nomograms, and the radioactivity in I mL serum was extrapolated to the total plasma volume. Since all radioactivity was associated with the serum, absolute values in the serum represented the total activity in the vascular compartment. Estimates of plasma volume were extrapolated from lean body mass nomograms.
The patient's serum was studied before, immediately following, and as late as 24 hours after radiolabeled MoAb infusion by standard nonreducing SDS-PAGE electrophoresis. The radioimmunoconjugate was also studied alone by this method and after dispersion in a normal control human serum. Gamma radioactivity emitted by '"In and "Y (Bremsstrahlung) was determined by cutting gels into nine 1-cm slices and counting the slices in an auto-gamma well counter. The counts in each slice were calculated as a percentage of the total radioactivity in all slices.
As a further assay for in vivo alterations of the MoAb, IOO-pL aliquots of the patient's serum, and other materials used in the SDS-PAGE experiments, were administered IV to 6 to 8 week-old balbk mice, and the animals were killed 4 hours later. The tissues, including blood, liver, kidney, spleen, and bone, were collected, and the solid tissues were washed twice in saline and wet-weighed on an analytical balance. Counting was performed on a gamma scintillation counter along with a standard prepared from the injectate. These data were then reduced to the percent injected dose of tracer incorporated per organ and per gram of tissue. Dosimetry calculations. I ' 'In-labeled MoAb was initially demonstrated to have the same kinetics and distribution as '"Y-labeled MoAb in the nude mouse-human tumor model." This allowed the y-emitting "'In-labeled MoAbs to be used to predict the kinetics and distribution of "Y (a pure P-emitting radiopharmaceutical). This concept has been partially validated in our human studies herein in that '"Y-and "'In-labeled MoAb kinetics in the vascular compartment are virtually identical.
Based on these data, we concluded that "Y distribution could be predicted in a patient. A known quantity of the "'In injectate was kept and counted daily on the gamma camera to act as a decay standard. The patient was then administered a known quantity of the radiopharmaceutical and imaged at the times previously indicated. "Spot" views were obtained over the anterior and posterior surfaces of each patient. Each day, the patient was imaged, with positioning Studies of in vivo binding of anti-Id MoAbs. maintained constant using a laser positioning system (accurate within 2 mm). Windows were set over the organs in question. Counts per minute per organ were then obtained over the periods indicated. These values, in tum, were converted into disintegrations per minute using the efficiency of the gamma camera for "'In. Intravascular kinetics were determined by counting samples of the patients. blood obtained at the times indicated. Volumes of the various organs were determined based on computed tomography (CT) using I-cm sections. Bodily excretions for '"In were estimated. The collective data were reduced using a computer program that allows quantitation of the amount of radioactivity per organ. Standard MIRD (Medical Internal Radiation Dose) calculations were then used for radiation dose calculations. Radiation absorbed-dose estimates in cGy were obtained for the dose of "'In injected, and calculations were performed to obtain the corresponding cGy dose for 10 mCi '"Y, ing identical biodistribution for the two radioisotopes.
The assignment of complete response was made when all clinical radiologic and scintigraphic evidence of tumor had disappeared for at least 4 weeks during which no new lesions developed. The assignment of partial response was made when the sum of the products of the perpendicular diameters (as accessed by CT) of measurable tumor lesions had decreased by at least 50%, lasting for at least 4 weeks during which no new lesions developed. The assignment of stable disease was made when there was less than a 25% increase in the sum of the products of the perpendicular diameters of measurable tumor sites lasting for at least 4 weeks. The assignment of progressive disease was made when there was an increase of at least 25% of the sum of the products of the perpendicular diameters of measurable tumor sites, progression of any obvious lesion, or occurrence of a new lesion. twice, once with a small clearing dose (50 mg) of MoAb before 0.5 mCi "'In, and a second time with a larger clearing dose (500 mg) of MoAb before imaging with approximately 5.0 mCi "'In. In all cases studied, the 500-mg clearing dose provided better imaging resolution, and optimal imaging results were obtained on films at or later than 72 hours following "'In MoAb. Examples of tumor targeting seen in patient no. 2 (treated with an anti-pId MoAb) and patient no. 3 (treated with an anti-sId MoAb) are shown in Figs 1 and 2, respectively. In general, MoAb scans appeared more sensitive than CT in the detection of tumor. Lesions that were at least 1 cm in diameter were imaged. Dosimetry estimates from the first five patients were made by injecting '"In MoAb, assuming nearidentical distribution for "Y MoAb and manipulating the equations as though 10 mCi 90Y MoAb was administered. These data are shown in Table 3 . Eighty to 430 cGy/lO mCi "Y MoAb injected was delivered to tumor sites in patients with tumor sites that were technically assessable by dosimetry. Patient no. 5 underwent a lymphoma biopsy 48 hours Dosimetry. The therapeutic results and observed toxicity are shown in Tables 4 and 5 , respectively. CT scans of the chest and pelvis of patient no. 5 before, during, and after therapy are shown in Figs 3A and B. Patient no. 6 achieved a complete response in three cycles of treatment (Fig 4) and relapsed at 10 months from protocol entry. The time from protocol entry to progression of disease varied from 1 to 12 months for the nine patients studied.
RESULTS
Criteria
Toxicities were mild and well tolerated, as shown in Table  5 . All patients except no. 1 were treated in the outpatient setting. The most severe infusion-related toxicity was transient hypotension in patient no. 1, related to a rapid infusion Tumor response and toxicity of rherupy. rate (150 mgh) of unlabeled clearing MoAb before injection of a '"In MoAb imaging dose. This patient was known to have high levels of circulating Id. The patient was treated with fluids, benadryl, and epinephrine, and monitored overnight in the hospital. There were no further sequelae. The patient had only mild mucosal congestion on repeat MoAb infusion at a slower rate. Further study revealed ongoing complement fixation, presumably secondary to Id-anti-Id immune complex formation. Patient no. 7 had late development of a progressive mixed motor and sensory neuropathy after receiving two cycles of anti-Id approximately 8 weeks apart. Muscle and nerve biopsies failed to demonstrate either MoAb or immune complexes, and the patient's neuropathy did not respond to steroids. This same patient developed progressive pancytopenia 6 months following a second course of 9oY MoAb therapy, after having recovered to grade 0 neutropenia and grade 1 thrombocytopenia at week 11, cycle 2. Repeat bone marrow analysis demonstrated hypo- For plasia. Autologous bone marrow was transfused, but reingraftment ultimately failed-the patient died 7 months after initiation of therapy with stable disease. No opportunistic infections, hospitalizations, or need for blood transfusions occurred except in patient no. 7. Abnormal liver function tests were observed only in patient no. 7. In addition to the hypotension reported, nonhematologic toxicities included mucosal congestion (present in each course administered to patient no. 3), which was easily controlled with oral diphenhydramine, and arthralgias experienced by patient no. 5, which were easily managed with nonsteroidal antiinflammatory agents. Patient no. 6 had nausea and vomiting requiring treatment with antiemetics during the first and second but not the third course of treatment. One further patient (data not shown) developed mild hypotension in response to an initial clearing dose (small in quantity) of MoAb, and did not receive further treatment. The etiology of the hypotension was not solved, and the decision was made to exclude the subject from the study.
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All but one patient continued with their normal daily routines with a performance status of 100%. HAMA were monitored each cycle and were not observed during therapy or follow-up evaluation for 19 courses administered to nine patients.
Assessment of tumor at relapse. Patient no. 1 had a transient therapeutic response followed by progression. A lymph node aspirate demonstrated persistent Id-positive lymphoma. Patient no. 2 underwent a complete remission following three courses of therapy; however, he relapsed in a new site 12 months after protocol enrollment. He had no response to a fourth course of 90Y anti-Id MoAb. Subsequent biopsy of his relapsed lymphoma revealed transformation to diffuse large-cell lymphoma (histology at entry was follicular mixed lymphoma), and flow-cytometric evaluation with a panel of MoAbs revealed no reactivity with his anti-Id MoAb, consistent with Id-negative lymphoma. Subsequent molecular studies of this lymphoma documented the same JH rearrangement (data not shown) consistent with relapse of the original lymphoma. Patient no. 4 was evaluated when she had disease progression after further chemotherapy and a relapse in the bone marrow. Immunophenotyping of the patient's bone marrow revealed Id-positive disease; however, the patient had severe symptomatic cytopenias and refused further 9oY MoAb therapy. Patient no. 5 had a partial response following two courses of treatment, but because of persistent grade 2 thrombocytopenia, he could not be re-treated with 90Y MoAb. At that time, his peripheral disease progressed in prior sites of involvement, and rebiopsy of the lymphoma confirmed persistent Id-positive lymphoma. Patient no. 6, who had a complete response, relapsed at 10 months in a new site with Id-negative cells derived from the original malignant clone.
In vivo binding of anti-Id. Lymph node biopsies were 
DISCUSSION
Both anti-sIds and anti-pids were used in this study. No apparent differences were noted between the radiopharmaceutical~ with regard to tumor targeting, pharmacokinetics, or toxicity. Characteristics of the tumor immunophenotype and treatment isotype (IgGI v IgG2A) did not result in obvious targeting or response differences.
The variable that appeared to correlate with tumor targeting was the attainment of free circulating mouse IgG.*'.*" The presence of high levels of circulating antigen has been associated with poor antitumor responses in previous studies," and probably contributed to the limited clinical benefit in patient no. 1. In the remaining pId MoAb-treated patients, clearing of circulating Id was easily attained and tumor targeting was accomplished, with high peak levels of free mouse IgG documented in all patients assayed.
The administered radiolabeled MoAbs appeared stable based on similarity to the pharmacokinetics of the unlabeled mouse IgG. This is confirmed by the results of the nonreducing serum SDS-PAGE. The serum half-life of radioactivity in the vascular compartment was 10 to 24 hours. Only one For personal use only. on November 16, 2017. by guest www.bloodjournal.org From patient displayed a significant difference in the serum halflife of "'In MoAb versus wY MoAb (patient no. 5, course 2). Based on the above data and the degree of toxicity in vivo, dissociation of wY or "'In from the MoAbs was considered unlikely. Reports of serum half-life values of other radiolabeled intact murine MoAbs have varied from 24 to 48 hours'* and occasionally longer. In the majority of the cases, levels of circulating antigen were much lower and far fewer antigen binding sites were available for complex formation2* than in this patient group. It should also be remembered that complex formation of serum antigen by unlabeled MoAb does not necessarily mean that antigen existing in the interstitial fluid spaces of normal tissues has also been bound. The possibility exists that antigen in the interstitial fluid spaces could have acted as a sump. thus shortening the serum half-life of the radiopharmaceutical.
Tumor targeting by RIS was accomplished in all patients, with no apparent differences between five patients receiving anti-pId MoAbs and four patients receiving anti-sId MoAb. The 500" clearing dose of unlabeled MoAb provided optimal tumor targeting in comparison to the 50" clearing dose. The necessity for a large clearing dose of MoAb in a patient with a low circulating Id level is most likely due to the need to clear or mask nonspecific intravascular binding sites or antigen sequestered in normal tissues. Indeed, little is known of antigen secretory rates and degradation rates in B-cell lymphoma, but such rates in other antigen-production systems can vary from static to e~traordinary.'~ The general distribution of "'In MoAb in the patients was consistent with that observed with other "'In MoAbs in other tumor systems. The liver is normally the most apparent organ on the scan, even in the absence of circulating antigen, partly due to its size and partly due to nonspecific uptake of the MoAbs. Hepatic uptake of MoAbs occurs even in the case of endogenously labeled murine MoAbs studied in murine models." When our patients were imaged using 50 instead of 500 mg clearing antibody, the liver acquired a great deal of the radiopharmaceutical, and the serum half-life decreased markedly. This was probably due to both intrahepatic and extrahepatic immune complex formation with the "'In
B
MoAb. The implication to be drawn from these data is that the best antigen system to target is one that does not circulate. The data indicate that nonspecific radiolabeled MoAb hepatic acquisition can be reduced to same extent through the use of unlabeled antibody, but it cannot be completely eliminated. RIS served as a sensitive tool for evaluating tumor response. "'In scans showed tumor regression consistent with a similar time course as shown by CT scans of tumor sites.
Dosimetric estimates of radiation absorbed doses calculated from "'In MoAb imaging scans are in the range of tumor dose estimates reported by others".I6 for responding tumors. Press et all5 studied high-dose '"I-MB-1 radioimmunotherapy of B-cell lymphoma and, based on biodistribution studies, did not administer therapeutic doses of radiolabeled MoAb to patients whose data indicated that normal organs would receive equal or greater doses of radiation than the tumor sites. Based on their observations, patients no. 4 and 5 in our study were not optimal candidates for high-dose therapy, and indeed, they were not able to receive enough radiopharmaceutical to allow a major response.
Lymphoma biopsy 48 hours after "'In MoAb administration (patient no. 5) yielded 0.0028% of injected "'In per gram of tissue, similar to observations in other studies involving lymphoma," as well as other tumor systems.'" The calculation was made from a single biopsy site, and tracer uptake may have varied from site to site. Animal model studies strongly indicate that uptake will vary not only with any specific tumor but also with the size of the tumor site." There are several theoretical causes of this phenomenon, but blood flow variances are probably the dominant feature. Our report documents the first experience with non-marrow-ablative, repetitive, anti-Id 90Y MoAb therapy in B-cell lymphoma. In general, the therapy was well tolerated. Eight of nine patients were treated as outpatients, with no significant radiation risk posed to health personnel or families and no requirements for patient shielding. These data, together with other studies using radiolabeled pan B MoAbs, suggest that radiolabeled MoAbs may play a role in the treatment of B-cell lymphoma.
